Swedish Financial Statements From 2010 to 2024
| SOBI Stock | SEK 307.80 6.60 2.19% |
Check Swedish Orphan financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Swedish Orphan's main balance sheet or income statement drivers, such as , as well as many indicators such as . Swedish financial statements analysis is a perfect complement when working with Swedish Orphan Valuation or Volatility modules.
Swedish |
Swedish Orphan Biovitrum Company Return On Equity Analysis
Swedish Orphan's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Swedish Orphan Return On Equity | 0.11 |
Most of Swedish Orphan's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Swedish Orphan Biovitrum is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Swedish Orphan Biovitrum has a Return On Equity of 0.1061. This is 100.44% lower than that of the Healthcare sector and 69.69% lower than that of the Drug Manufacturers - Specialty & Generic industry. The return on equity for all Sweden stocks is 134.23% lower than that of the firm.
Swedish Orphan Biovitrum Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Swedish Orphan's current stock value. Our valuation model uses many indicators to compare Swedish Orphan value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Swedish Orphan competition to find correlations between indicators driving Swedish Orphan's intrinsic value. More Info.Swedish Orphan Biovitrum is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers reporting about 0.52 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Swedish Orphan Biovitrum is roughly 1.91 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Swedish Orphan's earnings, one of the primary drivers of an investment's value.About Swedish Orphan Financial Statements
Swedish Orphan shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Swedish Orphan investors may analyze each financial statement separately, they are all interrelated. The changes in Swedish Orphan's assets and liabilities, for example, are also reflected in the revenues and expenses on on Swedish Orphan's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Swedish Orphan Biovitrum AB , an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, immunology, and genetic and metabolic diseases. Swedish Orphan Biovitrum AB is headquartered in Solna, Sweden. Swedish Orphan operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange. It employs 1185 people.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Swedish Stock Analysis
When running Swedish Orphan's price analysis, check to measure Swedish Orphan's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Swedish Orphan is operating at the current time. Most of Swedish Orphan's value examination focuses on studying past and present price action to predict the probability of Swedish Orphan's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Swedish Orphan's price. Additionally, you may evaluate how the addition of Swedish Orphan to your portfolios can decrease your overall portfolio volatility.